ZOLMITRIPTAN ODT TABLET (ORALLY DISINTEGRATING)
País: Canadà
Idioma: anglès
Font: Health Canada
Fitxa tècnica
(SPC)
04-03-2021
Alguns documents d’aquest producte actualment no estan disponibles, podeu enviar una sol·licitud al nostre servei d’atenció al client i us ho notificarem tan bon punt puguem obtenir-los.
Enviar sol.licitud.
Enviar sol.licitud.
ingredients actius:
ZOLMITRIPTAN
Disponible des:
PRO DOC LIMITEE
Codi ATC:
N02CC03
Designació comuna internacional (DCI):
ZOLMITRIPTAN
Dosis:
2.5MG
formulario farmacéutico:
TABLET (ORALLY DISINTEGRATING)
Composición:
ZOLMITRIPTAN 2.5MG
Vía de administración:
ORAL
Unidades en paquete:
100
tipo de receta:
Prescription
Área terapéutica:
SELECTIVE SEROTONIN AGONISTS
Resumen del producto:
Active ingredient group (AIG) number: 0134381001; AHFS:
Estat d'Autorització:
CANCELLED POST MARKET
Data d'autorització:
2021-04-02
Fitxa tècnica
PRODUCT MONOGRAPH
PR
ZOLMITRIPTAN
Zolmitriptan Film-Coated Tablets, House Standard
2.5 mg
PR
ZOLMITRIPTAN ODT
Zolmitriptan Orally Dispersible Tablets, House Standard
2.5 mg
5-HT1 RECEPTOR AGONIST
MIGRAINE THERAPY
DATE OF REVISION:
MARCH 4, 2021
PRO DOC LTÉE
2925, boul. Industriel
Laval, Québec
H7L 3W9
Submission Control No.: 248801
Zolmitriptan
Zolmitriptan PM-E.pdf
Pg. 1
_ _
_ZOLMITRIPTAN and ZOLMITRIPTAN ODT Product Monograph _
_Page 2 of 41 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...................................................... 3
SUMMARY PRODUCT INFORMATION
.....................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................
3
CONTRAINDICATIONS
...............................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................
5
ADVERSE REACTIONS
............................................................................................
12
DRUG INTERACTIONS
..............................................................................................
18
DOSAGE AND ADMINISTRATION
...........................................................................
20
OVERDOSAGE
............................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
.......................................................... 22
STORAGE AND STABILITY
......................................................................................
25
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................... 25
PART II: SCIENTIFIC INFORMATION
............................................................................
26
PHARMACEUTICAL
INFORMATION.......................................................................
26
CLINICAL
TRIALS........................................................................
Llegiu el document complet
